NCT03821272: A reported trial by University of Arkansas
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03821272 |
|---|---|
| Title | A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients in Remission to Reduce Recurrence Regardless of HPV Status |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 13, 2019 |
| Completion date | Feb. 3, 2025 |
| Required reporting date | Feb. 3, 2026, midnight |
| Actual reporting date | Aug. 1, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |